Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients

G. Cannella, G. La Canna, M. Sandrini, M. Gaggiotti, G. Nordio, E. Movilli, R. Maiorca

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

To obtain information on the effects of the correction of uremic anemia on cardiac function and size, nine normotensive dialyzed patients were studied before, during and six months after the start of i.v. treatment with recombinant human erythropoietin (rHuEPO). Pulsed-doppler echocardiographic determinations of the cardiac index (CI) and M-Mode echocardiographic estimations of the indexed left ventricular end diastolic diameter (LVEDDi), interventricular septum (IVSi), left ventricular posterior wall (LVPWi), with calculations of the left ventricular mass index (LVMi), were made on every occasion. Mean (± SD) hemoglobin (Hb) concentration before rHuEPO was 5.9 ± 1.3 g/dl and rose significantly (p <0.0001) up to the third month, then remained constant. Baseline CI (3.4 ± 0.6 l/min/m2bsa) was significantly higher (p <0.0001) than in healthy subjects (2.5 ± 0.5 l), and decreased after the third month to a value (2.8 ± 0.5 l) no longer different from that of controls. From pooled baseline and third month data, an inverse relationship between Hb and CI was found (p <0.0001). Baseline LVEDDi (32.7 ± 4.3 mm/m2bsa), IVSi (6 ± 1.1 mm/m2bsa) and LVPWi (5 ± 0.8 mm/m2bsa) were all significantly higher than in controls. After three months of therapy, the only change was a decrease in LVPWi while after six months all indices, including the LVMi, decreased to values no longer higher than in controls. From pooled baseline and six months data, an inverse relationship between Hb and LVMi was found (p <0.0001). We conclude that treatment of uremic patients rHuEPO is able to renormalize their already increased cardiac output soon after correction of the anemia. Recovery from left ventricular dilation and hypertrophy might also ensue provided enough time is allowed to elapse after relieving the anemia and correcting the cardiac output.

Original languageEnglish
Pages (from-to)272-278
Number of pages7
JournalClinical Nephrology
Volume34
Issue number6
Publication statusPublished - 1990

Fingerprint

High Cardiac Output
Erythropoietin
Anemia
Hemoglobins
Cardiac Output
Left Ventricular Hypertrophy
Dilatation
Healthy Volunteers
Therapeutics

Keywords

  • cardiac output
  • chronic anemia
  • chronic uremia
  • left ventricle
  • recombinant human erythropoietin

ASJC Scopus subject areas

  • Nephrology

Cite this

Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. / Cannella, G.; La Canna, G.; Sandrini, M.; Gaggiotti, M.; Nordio, G.; Movilli, E.; Maiorca, R.

In: Clinical Nephrology, Vol. 34, No. 6, 1990, p. 272-278.

Research output: Contribution to journalArticle

@article{46636ea7882c4596a9f5ccacad8b6894,
title = "Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients",
abstract = "To obtain information on the effects of the correction of uremic anemia on cardiac function and size, nine normotensive dialyzed patients were studied before, during and six months after the start of i.v. treatment with recombinant human erythropoietin (rHuEPO). Pulsed-doppler echocardiographic determinations of the cardiac index (CI) and M-Mode echocardiographic estimations of the indexed left ventricular end diastolic diameter (LVEDDi), interventricular septum (IVSi), left ventricular posterior wall (LVPWi), with calculations of the left ventricular mass index (LVMi), were made on every occasion. Mean (± SD) hemoglobin (Hb) concentration before rHuEPO was 5.9 ± 1.3 g/dl and rose significantly (p <0.0001) up to the third month, then remained constant. Baseline CI (3.4 ± 0.6 l/min/m2bsa) was significantly higher (p <0.0001) than in healthy subjects (2.5 ± 0.5 l), and decreased after the third month to a value (2.8 ± 0.5 l) no longer different from that of controls. From pooled baseline and third month data, an inverse relationship between Hb and CI was found (p <0.0001). Baseline LVEDDi (32.7 ± 4.3 mm/m2bsa), IVSi (6 ± 1.1 mm/m2bsa) and LVPWi (5 ± 0.8 mm/m2bsa) were all significantly higher than in controls. After three months of therapy, the only change was a decrease in LVPWi while after six months all indices, including the LVMi, decreased to values no longer higher than in controls. From pooled baseline and six months data, an inverse relationship between Hb and LVMi was found (p <0.0001). We conclude that treatment of uremic patients rHuEPO is able to renormalize their already increased cardiac output soon after correction of the anemia. Recovery from left ventricular dilation and hypertrophy might also ensue provided enough time is allowed to elapse after relieving the anemia and correcting the cardiac output.",
keywords = "cardiac output, chronic anemia, chronic uremia, left ventricle, recombinant human erythropoietin",
author = "G. Cannella and {La Canna}, G. and M. Sandrini and M. Gaggiotti and G. Nordio and E. Movilli and R. Maiorca",
year = "1990",
language = "English",
volume = "34",
pages = "272--278",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "6",

}

TY - JOUR

T1 - Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients

AU - Cannella, G.

AU - La Canna, G.

AU - Sandrini, M.

AU - Gaggiotti, M.

AU - Nordio, G.

AU - Movilli, E.

AU - Maiorca, R.

PY - 1990

Y1 - 1990

N2 - To obtain information on the effects of the correction of uremic anemia on cardiac function and size, nine normotensive dialyzed patients were studied before, during and six months after the start of i.v. treatment with recombinant human erythropoietin (rHuEPO). Pulsed-doppler echocardiographic determinations of the cardiac index (CI) and M-Mode echocardiographic estimations of the indexed left ventricular end diastolic diameter (LVEDDi), interventricular septum (IVSi), left ventricular posterior wall (LVPWi), with calculations of the left ventricular mass index (LVMi), were made on every occasion. Mean (± SD) hemoglobin (Hb) concentration before rHuEPO was 5.9 ± 1.3 g/dl and rose significantly (p <0.0001) up to the third month, then remained constant. Baseline CI (3.4 ± 0.6 l/min/m2bsa) was significantly higher (p <0.0001) than in healthy subjects (2.5 ± 0.5 l), and decreased after the third month to a value (2.8 ± 0.5 l) no longer different from that of controls. From pooled baseline and third month data, an inverse relationship between Hb and CI was found (p <0.0001). Baseline LVEDDi (32.7 ± 4.3 mm/m2bsa), IVSi (6 ± 1.1 mm/m2bsa) and LVPWi (5 ± 0.8 mm/m2bsa) were all significantly higher than in controls. After three months of therapy, the only change was a decrease in LVPWi while after six months all indices, including the LVMi, decreased to values no longer higher than in controls. From pooled baseline and six months data, an inverse relationship between Hb and LVMi was found (p <0.0001). We conclude that treatment of uremic patients rHuEPO is able to renormalize their already increased cardiac output soon after correction of the anemia. Recovery from left ventricular dilation and hypertrophy might also ensue provided enough time is allowed to elapse after relieving the anemia and correcting the cardiac output.

AB - To obtain information on the effects of the correction of uremic anemia on cardiac function and size, nine normotensive dialyzed patients were studied before, during and six months after the start of i.v. treatment with recombinant human erythropoietin (rHuEPO). Pulsed-doppler echocardiographic determinations of the cardiac index (CI) and M-Mode echocardiographic estimations of the indexed left ventricular end diastolic diameter (LVEDDi), interventricular septum (IVSi), left ventricular posterior wall (LVPWi), with calculations of the left ventricular mass index (LVMi), were made on every occasion. Mean (± SD) hemoglobin (Hb) concentration before rHuEPO was 5.9 ± 1.3 g/dl and rose significantly (p <0.0001) up to the third month, then remained constant. Baseline CI (3.4 ± 0.6 l/min/m2bsa) was significantly higher (p <0.0001) than in healthy subjects (2.5 ± 0.5 l), and decreased after the third month to a value (2.8 ± 0.5 l) no longer different from that of controls. From pooled baseline and third month data, an inverse relationship between Hb and CI was found (p <0.0001). Baseline LVEDDi (32.7 ± 4.3 mm/m2bsa), IVSi (6 ± 1.1 mm/m2bsa) and LVPWi (5 ± 0.8 mm/m2bsa) were all significantly higher than in controls. After three months of therapy, the only change was a decrease in LVPWi while after six months all indices, including the LVMi, decreased to values no longer higher than in controls. From pooled baseline and six months data, an inverse relationship between Hb and LVMi was found (p <0.0001). We conclude that treatment of uremic patients rHuEPO is able to renormalize their already increased cardiac output soon after correction of the anemia. Recovery from left ventricular dilation and hypertrophy might also ensue provided enough time is allowed to elapse after relieving the anemia and correcting the cardiac output.

KW - cardiac output

KW - chronic anemia

KW - chronic uremia

KW - left ventricle

KW - recombinant human erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=0025646631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025646631&partnerID=8YFLogxK

M3 - Article

C2 - 2073771

AN - SCOPUS:0025646631

VL - 34

SP - 272

EP - 278

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 6

ER -